Hospitals
Physicians
Clinical trials
Contact us
Links
National Cancer Institute - Community Clinical Oncology Program

 

CURRENTLY OPEN CLINICAL TRIALS

Dayton Clinical Oncology Program accesses clinical trials through its membership in cooperative research groups funded by the National Cancer Institute (NCI), and through the pharmaceutical industry.

For a listing of research groups and links to their web sites, go to the "Links to Other Sites" tab at the left.

Clinical Trial By Disease Site
(Click the links to advance to a specific section)

   


General Cancer Control Trials for Symptom Management

URCC-0701

Effects of Exercise on Cancer-Related Fatigue.

URCC-10055

Assessment Of Cognitive Function In Breast Cancer And Lymphoma Patients Receiving Chemotherapy At Pre-Treatment, Post-Treatment And At Six Month Follow-Up

Information and Referral Form

Back to top

BRAIN

TREATMENT:

A071101

Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resective Recurrent Glioblastoma Multiforme (GBM)

Brain Cancer Contol:

A221101

Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme

Back to list

BREAST

BREAST CANCER CONTROL:

A221102

TitleStudy of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias

E1Z11

Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NSABP B-43

Herceptin Given Concurrently with Radiation Therapy vs Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

S1202

Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

Back to list

HER2-

A011106

ALTernate approaches for Clinical Stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant TrEatment (ALTERNATE) in postmenopausel women:

S1207

Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

HER2+:

NSABP B-52

Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

FB-7

A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer

METASTATIC:

E2108

The Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

E3108 Temporarily closed to accrual

Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen

Nodal:

A011202

Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

NSABP B-47

Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

NSABP B-51

Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

S1007

Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

Back to list

GASTROINTESTINAL:

COLORECTAL CANCER PREVENTION:

OCCPI

Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

S0820

Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

COLORECTAL TREATMENT:

CALGB-80702

6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

ESOPHAGEAL:

RTOG-1010

Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma

S1201

Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer

PANCREATIC:

E2211

Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumor

S1115

Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy

RECTAL:

N1048

Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

 

Back to list

GENITOURINARY:

PROSTATE:

S1216

Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

RENAL:

A031203 Pending approval

Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

E2810

Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

S0931

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy

S1107

Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma

Back to list

GYN:

GYN Cancer Control

GOG-0273

Chemotherapy toxicity in elderly women with ovarian, primary peritoneal or fallopian tube cancer

 

LEUKEMIA:

AML:

E2906

Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)

S1203

Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)

CLL:

A041202

Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

E1912

Study of Ibrutinib (PCI- 32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)


LEUKEMIA OTHER:

551-1019 Temporarily closed to accrual

Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

E1908

Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab.

E1910

Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

LUNG:


NSCLC:

E5508

Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paxlitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

S0819

Carboplatin/Taxol or Carboplatin/Taxol/Avastin with/without Concurrent Erbitux in Patients with Advanced Non-Small Cell Lung Cancer.

Other:

S0905

Study of Cediranib (NSC#732208) versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma

LYMPHOMA:

Lymphoma/Other

CALGB-50904

Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma

E1411

Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)

Back to list

MELANOMA:

E1609

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

N0879

Carbo/Taxol/Avastin +/- Afinitor for Therapy of Metastatic Malignant Melanoma.

Back to list

MYELOMA:

E1A11

Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma

 

Back to list

SARCOMA:

A091102

Study of MLN8237 in Advanced/ Metastatic Sarcoma

OTHER:

A021202 Pending approval

Pazopanib (NSC #737754, IND #75648) Versus Placebo in Patients With Progressive Carcinoid Tumors

N0392

Assessment of Patient Satisfaction with Participation on Phase II/III NCCTG Clinical Trials.

 

QUESTIONS?

CONTACT DAYTON CLINICAL ONCOLOGY PROGRAM
OR ASK YOUR PHYSICIAN
"Is There a Clinical Trial For Me?"

Contact Us

By Phone:
(937) 775-1350
Fax:
(937) 775-1358
By Mail:
Dayton Clinical Oncology Program
3123 Research Blvd., Suite 150
Dayton, Ohio 45420